Lipocine chairman resigns; board names new leader

Lipocine Inc. reported that on April 16, 2026, Dr. Spyros Papapetropoulos resigned from its Board of Directors effective immediately.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lipocine Inc. reported that on April 16, 2026, Dr. Spyros Papapetropoulos resigned from its Board of Directors effective immediately. He had served since 2022 as Chairman, Lead Independent Director, and a member of the Board’s compensation committee.

The company stated that Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on Lipocine’s strategic direction. On April 20, 2026, the Board appointed R. Dana Ono as the new Chairman of the Board and Lead Independent Director, ensuring continuity in independent board leadership.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Director resignation date: April 16, 2026 New chairman appointment date: April 20, 2026 Filing signature date: April 21, 2026

3 metrics

Director resignation date April 16, 2026 Effective date of Dr. Papapetropoulos’s board resignation

New chairman appointment date April 20, 2026 Date Board appointed R. Dana Ono as Chairman and Lead Independent Director

Filing signature date April 21, 2026 Date CEO Mahesh V. Patel signed the disclosure

Key Terms

Lead Independent Director, compensation committee, emerging growth company, strategic direction

4 terms

Lead Independent Director financial

"was the Board’s Chairman and Lead Independent Director and a member"

A lead independent director is a board member who is not part of company management and is chosen to coordinate and represent the other independent directors, often running sessions without the CEO, helping set meeting agendas, and serving as a liaison between shareholders and the board. For investors, this role signals stronger, more balanced oversight—like a neutral referee who helps ensure decisions are fair, transparent and focused on protecting shareholder interests.

compensation committee financial

"and Lead Independent Director and a member of the Board’s compensation committee"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

emerging growth company regulatory

"405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

strategic direction financial

"evolving board dynamics arising from differing views on the Company’s strategic direction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Lipocine (LPCN) director Spyros Papapetropoulos resign from the board?

Dr. Spyros Papapetropoulos resigned from Lipocine’s board on April 16, 2026. The company said his decision reflected competing professional commitments and evolving board dynamics arising from differing views on Lipocine’s strategic direction, highlighting a change in how leadership views the company’s future path.

What roles did Dr. Papapetropoulos hold at Lipocine (LPCN) before resigning?

Before resigning, Dr. Papapetropoulos served as Lipocine’s Board Chairman, Lead Independent Director, and a member of the Board’s compensation committee. He had been on the Board since 2022, giving him a central role in both oversight and governance of executive pay decisions.

Who became Lipocine (LPCN) Chairman after Dr. Papapetropoulos resigned?

On April 20, 2026, Lipocine’s Board appointed R. Dana Ono as Chairman of the Board and Lead Independent Director. This appointment fills the leadership gap created by Dr. Papapetropoulos’s resignation and maintains an independent director in the board chair role.

When did Lipocine (LPCN) disclose the board leadership changes?

Lipocine disclosed the leadership changes in a report signed by President and Chief Executive Officer Mahesh V. Patel dated April 21, 2026. The filing outlines the resignation on April 16 and the subsequent appointment of R. Dana Ono on April 20, 2026.

Did Lipocine (LPCN) mention any change to its executive management team?

The company did not report changes to its executive management team in this disclosure. It specifically described the resignation of director and Chairman Dr. Papapetropoulos and the Board’s appointment of R. Dana Ono as Chairman and Lead Independent Director, leaving executive roles unchanged in this update.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/21/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

April 16, 2026

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 16, 2026, Spyros Papapetropoulos informed the Board of Directors (the “Board”) of Lipocine Inc. (the “Company”) that he resigned as a member of the Board effective immediately. Dr. Papapetropoulos has served as a member of the Board since 2022 and was the Board’s Chairman and Lead Independent Director and a member of the Board’s compensation committee. On April 20, 2026, the Board appointed R. Dana Ono as Chairman of the Board and Lead Independent Director.

Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on the Company’s strategic direction.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		LIPOCINE INC.

Date:	April 21, 2026	By:	/s/ Mahesh V. Patel
			Mahesh V. Patel
			President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents